Related references
Note: Only part of the references are listed.Predictors of Heightened Platelet Reactivity Despite Dual-Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention
Matthew J. Price et al.
AMERICAN JOURNAL OF CARDIOLOGY (2009)
Relation of Cytochrome P450 2C19 Loss-of-Function Polymorphism to Occurrence of Drug-Eluting Coronary Stent Thrombosis
Betti Giusti et al.
AMERICAN JOURNAL OF CARDIOLOGY (2009)
Cardiovascular Death and Nonfatal Myocardial Infarction in Acute Coronary Syndrome Patients Receiving Coronary Stenting Are Predicted by Residual Platelet Reactivity to ADP Detected by a Point-of-Care Assay A 12-Month Follow-Up
Rossella Marcucci et al.
CIRCULATION (2009)
Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention
Dirk Sibbing et al.
EUROPEAN HEART JOURNAL (2009)
Platelet Reactivity After Clopidogrel Treatment Assessed With Point-of-Care Analysis and Early Drug-Eluting Stent Thrombosis
Dirk Sibbing et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study
Jean-Philippe Collet et al.
LANCET (2009)
Cytochrome P-450 Polymorphisms and Response to Clopidogrel.
Jessica L. Mega et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Genetic Determinants of Response to Clopidogrel and Cardiovascular Events.
Tabassome Simon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Impact of bivalirudin or unfractionated heparin on platelet aggregation in patients pretreated with 600 mg clopidogrel undergoing elective percutaneous coronary intervention
Dirk Sibbing et al.
EUROPEAN HEART JOURNAL (2008)
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation
Matthew J. Price et al.
EUROPEAN HEART JOURNAL (2008)
Aspirin and clopidogrel with or without phenprocoumon after drug eluting coronary stent placement in patients on chronic oral anticoagulation
N. Sarafoff et al.
JOURNAL OF INTERNAL MEDICINE (2008)
Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin
Martine Gilard et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Calcium-Channel Blockers Reduce the Antiplatelet Effect of Clopidogrel
Jolanta M. Siller-Matula et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents
Dietmar Trenk et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Cytochrome P4502C19 loss-of-function polymorphism, but not CYP3A4 IVS10+12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients
Betti Giusti et al.
PHARMACOGENETICS AND GENOMICS (2007)
Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel
J. T. Brandt et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease
Dominick J. Angiolillo et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of Clopidogrel before percutaneous coronary intervention
Dirk Sibbing et al.
AMERICAN JOURNAL OF CARDIOLOGY (2007)
Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis
Piergiovanni Buonamici et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently
N. A. Farid et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Variability in individual responsiveness to clopidogrel - Clinical implications, management, and future perspectives
Dominick J. Angiolillo et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Increased risk in patients with high platelet amregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention - Is the current antiplatelet therapy adequate?
Kevin P. Bliden et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement
Willibald Hochholzer et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Cytochrorne P4502C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects
Jean-Sebastien Hulot et al.
BLOOD (2006)
Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation
Tobias Geisler et al.
EUROPEAN HEART JOURNAL (2006)
ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention)
SC Smith et al.
CIRCULATION (2006)
Guidelines for percutaneous coronary interventions -: The task force for percutaneous coronary interventions of the European Society of Cardiology
S Silber et al.
EUROPEAN HEART JOURNAL (2005)
Variability in platelet responsiveness to clopidogrel among 544 individuals
VL Serebruany et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro
M Ufer et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Clopidogrel for coronary stenting - Response variability, drug resistance, and the effect of pretreatment platelet reactivity
PA Gurbel et al.
CIRCULATION (2003)
Identification of the platelet ADP receptor targeted by antithrombotic drugs
G Hollopeter et al.
NATURE (2001)